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Adjuvant Chemotherapy Based on the In Vitro Histoculture
Drug Response Assay for Non-small Cell Lung Cancer
Improves Survival
Masayuki Tanahashi, MD, Hiroshi Niwa, MD, Haruhiro Yukiue, MD, Eriko Suzuki, MD,
Hiroshi Haneda, MD, and Naoko Yoshii, MD
Background: In this study, we analyzed the usefulness of adjuvant
chemotherapy for non-small cell lung cancer based on the histocul-
ture drug response assay (HDRA).
Methods: From September 2001 to December 2008, 65 patients
with pathologic stage II or higher non-small cell lung cancer who
underwent surgery received two-cycle HDRA-based adjuvant che-
motherapy. Chemosensitivity to cisplatin, carboplatin, paclitaxel,
docetaxel, gemcitabine, and irinotecan was examined by the HDRA.
All patients were classified according to the number of administered
HDRA-positive drugs: the prediction-sensitive group (PSG) (n 
31) comprised patients treated with two HDRA-positive drugs and
the prediction-nonsensitive group (PNSG) (n 34) comprised those
treated with a combination of one HDRA-positive and one HDRA-
negative drug or two HDRA-negative drugs. The clinical outcomes
of the two groups were analyzed.
Results: The overall 5-year survival rate of the PSG was 82.4%. On
the other hand, that of the PNSG was 40.1%. There were significant
differences between the two groups (p  0.03). The 5-year disease-
free survival rate was more favorable in the PSG than in the PNSG
(PSG: 56.5%, PNSG: 30.1%, p  0.05). Multivariate analysis
showed that chemotherapy based on the HDRA was a significant
prognostic factor (p  0.03).
Conclusions: The prognosis of patients treated with two HDRA-
positive drugs was significantly better than that of those treated with
one HDRA-positive drug or HDRA-negative drugs. Adjuvant che-
motherapy based on the in vitro HDRA may be useful to improve
survival in patients who have undergone surgery.
Key Words: Histoculture Drug Response Assay, Adjuvant chemo-
therapy, Nonsmall cell lung cancer.
(J Thorac Oncol. 2010;5: 1376–1381)
Lung cancer is the leading cause of cancer death in manycountries. Surgery is the best potentially curative treatment
modality for patients with non-small cell lung cancer (NSCLC).
NSCLC accounts for about 80 to 85% of all lung cancer.
Although the discovery rate of early-stage lung cancer has
increased due to the spread of computed tomography-based
checkup, lung cancer discovered at an advanced stage is still
common. Moreover, it has been reported that the greater part of
relapse in patients who have undergone complete resection
involves distant metastasis, so it is insufficient solely in local
treatment such as surgery. To improve the postoperative survival
of patients with NSCLC, the development of effective postop-
erative therapy is essential. Large numbers of clinical trials
involving multimodality therapy are based on such a back-
ground, and many trials showing the usefulness of adjuvant
chemotherapy have recently been reported.1–6 The International
Adjuvant Lung Cancer Collaborative Group Trial demon-
strated a 4.1% improvement in survival in patients with
stages I to III NSCLC.1 The JBR10 trial demonstrated a 15%
improvement in 5-year survival in an adjuvant chemotherapy
arm involving stage IB or II patients.2 The Adjuvant Navel-
bine International Trialist Association trial reported that the
overall survival at 5 years improved by 8.6% in the chemo-
therapy arm and that this survival rate was maintained at 7
years (8.4%) in stage II and IIIA patients.3 Lung Adjuvant
Cisplatin Evaluation, a pooled analysis of five randomized
trials that included 4584 patients, showed a significant overall
survival advantage for all patients with stage II or III cancer
who received cisplatin (CDDP)-based adjuvant chemotherapy.4
However, no definite regimens of adjuvant chemotherapy for
NSCLC have been determined. Administering inappropriate
anticancer drugs has adverse effects on patients. Recently, an
in vitro drug response assay, developed over more than four
decades, was introduced to individualize chemotherapy as an
alternative to empiric therapy. Theoretically, use of the in
vitro drug response assay could lead to more rational treat-
ment decisions. Freeman and Hoffman7 introduced a devel-
opmental methodology called collagen sponge-gel-supported
histoculture, which allows diverse human tumors obtained
directly from surgery to grow at a high frequency in vitro for
long periods and established the histoculture drug response
assay (HDRA). Several researchers in the fields of gastric and
esophageal cancer have reported that HDRA-based adjuvant
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chemotherapy has the potential to improve patient survival8–10;
however, to the best of our knowledge, no work has been
done to elucidate the clinical usefulness of the HDRA for
NSLC in an adjuvant setting. So, we retrospectively investi-
gated the usefulness of adjuvant chemotherapy based on the
HDRA for patients with NSCLC.
PATIENTS AND METHODS
Patients
From September 2001 to December 2008, 832 patients
underwent surgery with curative intent for primary NSCLC in
our institute. Of these, tissue samples of primary tumors were
collected at surgery from 482. Of the 482 patients, 68 could
not undergo sufficient HDRA measurement because of insuf-
ficient cell viability or tissue amounts. The remaining 414
patients (85.8%) could be evaluated regarding their chemo-
sensitivity to CDDP, carboplatin (CBDCA), irinotecan
(SN38), paclitaxel (PTX), docetaxel (DOC), and gemcitabine
(GEM). A mean of 4.8  1.5 (min–max: 1–6) drugs were
tested in the 414 patients. The patients with pathologic stage
II or more advanced disease underwent two-cycle adjuvant
chemotherapy. If patients showed two or more HDRA-posi-
tive drugs, we selected the two strongest HDRA-positive
drugs while excluding combinations of the same category
(CDDP and CBDCA, PTX, and DOC). If patients showed
only one HDRA-positive drug, we selected this drug and the
strongest HDRA-negative drug. If patients showed no
HDRA-positive drug, we selected the strongest platinum
agent and the most powerful drug among nonplatinum agents
under informed consent. If a patient showed a poor postop-
erative performance status (World Health Organization per-
formance status 2 or higher), advanced age (more than 75
years), or severe complications, we performed adjuvant chemo-
therapy with a single agent using HDRA results. Of the 414
patients, 187 showed pathologic stage II or higher. Of the
187 patients, 143 received adjuvant chemotherapy. Of those,
78 patients were excluded from this study because of single-
agent or insufficient chemotherapy. So, in this study, we
retrospectively reviewed the remaining 65 patients who re-
ceived two-cycle HDRA-based adjuvant chemotherapy with
a doublet regimen. All patients showed World Health Orga-
nization performance status 1 or lower and had no history of
concurrent malignant disease. No patients received postoper-
ative radiotherapy.
Pathologic staging was performed according the sev-
enth edition of the tumor, node, metastasis classification of
the Union Internationale Contre le Cancer for lung cancer.
Our institutional review board for clinical practice ap-
proved this study, and written informed consent regarding the
use of the HDRA was obtained from all patients before
surgery.
Histoculture Drug Response Assay
Tumor tissue was freshly harvested from surgically re-
sected specimens, excluding necrotic or infected portions,
washed in Hanks solution, minced into pieces of approximately
10 mg, and then placed on prepared collagen surfaces in 24-well
microplates. Plates were incubated for 7 days at 37°C with 5%
CO2 in Roswell Park Memorial Institute 1640 medium supple-
mented with 20% fetal calf serum and anticancer agents. Con-
centrations of drugs were 20 g/mL for CDDP, 25 g/mL for
CBDCA, 0.2 g/mL for irinotecan (SN38), 100 g/mL for
DOC, 40 g/mL for PTX, and 1000 g/mL for GEM. After
histoculture, 100 L of Hanks balanced salt solution containing
0.1 mg/mL of type I collagenase (Sigma) and 100 L of 3-
(4,5-dimethyl-2-thiazotyl)-2,5-diphenyl-2H-tetrazoliumbromide
(MTT) solution dissolved in 5 mg/mL of phosphate buffer
solution was added to each culture well and incubated for
another 16 hours. After extraction with dimethyl sulfoxide,
the absorbance of the solution in each well was read at 540
nm.11,12 The absorbance per gram of cultured tumor tissue
was calculated from the mean absorbance of tissue from
culture wells, and the tumor tissue weight was determined
before culture.
The rate of inhibition was calculated using the follow-
ing formula:
Inhibition rate (%)
 (1  Mean absorbance of treated tumor/Weight/
Mean absorbance of control tumor/Weight)  100
The HDRA was regarded as applicable when the mean
absorbance of extracted formazan at 540 nm of the control
tumor was 15 or more per gram. When the inhibition rate of
the drug was a negative value, it was regarded as zero, which
meant zero chemosensitivity.
The concentration and cutoff inhibition rate of antican-
cer drugs were determined according to previously reported
clinical response rates of each drug when administered as a
single agent (Table 1).13 The cutoff level was not changed
according to the histology. An anticancer drug with an inhi-
bition rate above the cutoff level was classified as an HDRA-
positive drug.
Statistical Analyses
Categorical variables were analyzed by means of 2
analysis and the unpaired t test. Survival was estimated by
means of the Kaplan-Meier method, and differences in sur-
vival were determined using log-rank analysis. The Cox
proportional hazards regression model was used to assess the
TABLE 1. Anticancer Drug Concentration and Cutoff
Inhibition Rate
Anticancer Drugs
Concentration
(g/ml)
Cutoff Inhibition
Rate (%)
CDDP 20 50
CBDCA 25 30
PTX 40 70
DOC 100 40
GEM 1,000 30
CPT-11 (SN38) 0.2 50
CBDCA, carboplatin; CDDP, cisplatin; DOC, docetaxel; GEM, gemcitabine; PTX,
paclitaxel.
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results of multivariate analysis of independent prognostic
factors, which include the HDRA, age, gender, pathologic T
factor, pathologic N factor, pathologic M factor, and opera-
tive curability. Zero time was the date of pulmonary resec-
tion, and the final end point of overall survival was death
attributable to cancer or due to a cause other than cancer. The
final end point of disease-free survival was the date of
recurrence and that of the last follow-up or the date of death
in the absence of recurrence. Not all recurrences were con-
firmed pathologically. A p value of less than 0.05 was
considered significant.
RESULTS
From September 2001 to December 2008, there were
65 patients who received HDRA-based adjuvant chemother-
apy with a doublet regimen. The 65 patients were divided into
a prediction-sensitive group (PSG) (n  31) and prediction-
nonsensitive (PNSG) group (n 34) according to the number
of administered HDRA-positive drugs. The PSG consisted of
patients treated with two HDRA-positive drugs, and the
PSNG comprised patients treated with a combination of one
HDRA-positive drug and one HDRA-negative drug or two
HDRA-negative drugs. The overall follow-up period ranged
from 6.5 to 85.1 months, with a median of 29.2 months (mean
follow-up: 29.2  21.1 months). Table 2 shows the charac-
teristics of the PSG and PSNG. Overall, 15 (23%) patients
had postoperative stage IIA disease, 13 (20%) had stage IIB
disease, 28 (43%) had stage IIIA disease, 2 (3%) had stage
IIIB disease, and 7 (10%) had stage IV disease. Seven
patients with postoperative stage IV underwent incomplete
resection (slight dissemination in six and slight malignant
effusion in one). No differences in the sex, age, histology,
pathologic stage, pathologic T factor, pathologic N factor,
pathologic M factor, curability of surgery, or epidermal
growth factor receptor gene mutation status were observed
between the two groups. Adjuvant chemotherapy regimens of
the PSG were 80 mg/m2 PTX on days 1, 8, and 15 plus 80
mg/m2 CDDP on day 1 in 12; 60 mg/m2 PTX on days 1, 8,
and 15 plus 60 mg/m2 camptothecin-11 on days 1, 8, and 15
in 10; 80 mg/m2 PTX on days 1, 8, and 15 plus an area under
the curve (AUC) of 5 mg/mL per minute CBDCA on day 1
in 6; and 60 mg/m2 DOC on day 1 plus 80 mg/m2 CDDP on
day 1 in 3. Those of the PNSG were 80 mg/m2 PTX on days
1,8, and 15 plus 80 mg/m2 CDDP on day 1 in 8; 60 mg/m2
PTX on days 1, 8, and 15 plus 60 mg/m2 camptothecin-11 on
days 1, 8, and 15 in 8; 80 mg/m2 PTX on days 1, 8, and 15
plus an AUC of 5 mg/mL per minute CBDCA on day 1 in 9;
60 mg/m2 DOC on day 1 plus 80 mg/m2 CDDP on day 1 in
6; 30 mg/m2 DOC on days 1 and 15 plus an AUC of 3 mg/mL
per minute CBDCA on days 1 and 15 in 2; and 1000 mg/m2
GEM on days 1, 8, and 15 plus an AUC of 5 mg/mL per
minute CBDCA on day 1 in 1. In both groups, all patients
received two-cycle chemotherapy.
The overall 5-year survival rate was 82.4% for the PSG
and 40.1% for the PNSG (Figure 1). A significant difference
between the two groups was observed (p  0.03).
During the follow-up period, recurrence occurred in
29.0% (9 of 31 patients) of the PSG (pulmonary metastasis in
five, supraclavicular lymph node metastasis in one, kidney
metastasis in one, bone metastasis in one, and dissemination
in one) and in 55.8% (19 of 34 patients) of the PNSG
(pulmonary metastasis in seven, mediastinal lymph node
metastasis in five, bone metastasis in three, brain metastasis
in two, and dissemination in two). The rate of relapse was
lower in the PSG than in the PNSG (p  0.02). The 5-year
disease-free survival rates were 56.5% in the PSG and
TABLE 2. Characteristics of Patients with NSCLC Who Underwent Adjuvant
Chemotherapy Based on the HDRA
Characteristics
Prediction-Sensitive
Group (n  31)
Prediction-Nonsensitive
Group (n  34) p
Males/females 23/8 27/7 0.61
Age (mean  SD) 59.7  10.2 61.3  7.0 0.45
Adenocarcinoma/SqCC/Others 18/11/2 24/8/2 0.46
pStage IIA/IIB/IIIA/IIIB/IV 3/9/15/0/4 12/4/13/2/3 0.08
pT1a/T1b/T2a/T2b/T3/T4 2/2/4/7/15/1 1/6/11/2/12/2 0.11
pN0/N1/N2 9/9/13 7/13/14 0.64
pM0/M1a/M1b 27/4/0 31/3/0 0.59
Curability: complete/incomplete 27/4 31/3 0.59
EGFR mutation: positive/negative/unknown 10/11/10 5/17/12 0.09
Adjuvant chemotherapy regimen
PTX  CDDP 12 8
PTX  CPT-11 10 8
PTX  CBDCA 6 9
DOC  CDDP 3 6
DOC  CBDCA 0 2
GEM  CBDCA 0 1
CBDCA, carboplatin; CDDP, cisplatin; CPT-11, irinotecan; DOC, docetaxel; GEM, gemcitabine; HDRA, Histoculture
Drug Response Assay; NSCLC, non-small cell lung cancer; PTX, paclitaxel; SqCC, squamous cell carcinoma.
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30.1% in the PNSG (Figure 2). The disease-free survival
rate of the PSG was more favorable than that of the PNSG
(p  0.05).
Moreover, Table 3 shows the results of multivariate
analysis of independent prognostic factors in patients who
underwent adjuvant chemotherapy based on the HDRA, dem-
onstrating that patients subjected to adjuvant chemotherapy
using two HDRA-positive drugs showed a significantly
longer survival than those who underwent adjuvant chemo-
therapy using one HDRA-positive drug or HDRA-negative
drugs (p  0.037).
DISCUSSION
The findings of this retrospective study showed that
adjuvant chemotherapy with two HDRA-positive drugs im-
proved the overall and disease-free survival rates in patients
with NSCLC.
We have been measuring the chemosensitivity of lung
cancer tissues to various drugs using the HDRA since Sep-
tember 2001 and applied the HDRA results to adjuvant
chemotherapy for NSCLC. We examined the sensitivity of
surgical specimens to CDDP, CBDCA, SN38, PTX, DOC,
and GEM. We did not examine the sensitivity to vinorelbine
in this study because its concentration and cutoff level have
not been determined. However, we recently started to exam-
ine the sensitivity of vinorelbine.
Several studies concerning chemosensitivity tests for
lung cancer were previously reported. They used the MTT
assay,14 human tumor clonogenic assay,15 HDRA,13,16 differ-
ential staining toxicity assay,17–19 adenosine triphosphate
(ATP) assay,20,21 extreme drug resistance assay,22–24 and
collagen droplet embedded culture drug sensitivity test (CD-
DST).25,26 Some studies indicated the clinical usefulness of
chemosensitivity tests for lung cancer. Kolek et al.14 reported
that a combination of CBDCA-based neoadjuvant chemother-
apy, surgical resection, and adjuvant chemotherapy achieved
satisfactory survival rates in stage IIIA NSCLC, especially in
patients with the complete resection of the tumor and those
given MTT-directed adjuvant treatment and suggested that
MTT testing may help optimize adjuvant chemotherapy.
Moon et al.21 investigated correlations between the ATP
assay and clinical outcomes after ATP assay-guided plati-
num-based chemotherapy in unresectable NSCLC. In that
study, the positive/negative predictive values were 61.1% and
78.6%, with a predictive accuracy of 68.8%. The platinum-
sensitive group showed a more favorable clinical response
(p  0.036), longer progression-free survival (p  0.060),
and longer overall survival (p  0.025). Kawamura et al.26
prospectively evaluated the clinical feasibility and efficacy of
CD-DST in unresectable NSCLC. CD-DST yielded success-
ful results in 61.3% of patients. Medican survival times of
patients treated with in vitro sensitive regimens were longer
than those of patients treated with empirical standard chemo-
therapy, and the response rate for the in vitro optimal regimen
was 72.7%. Yoshimasu et al.13 examined the chemosensitivities
of 359 lung cancer specimens. In this study, the applicability of
the HDRA was high at 97.4%, and good predictability (true-
positive and true-negative rates of 73.2% and 100%, respec-
FIGURE 2. Freedom-from-recurrence rates of patients in
the prediction-sensitive group (PSG, ) and prediction-non-
sensitive (PNSG, ‚) group. Patients in the PSG tended to
survive longer without recurrence than those in the PNSG
(p  0.05).
FIGURE 1. Postoperative survival rates of patients in the
prediction-sensitive group (PSG, ) and prediction-nonsensi-
tive (PNSG, ‚) group. Patients in the PSG survived signifi-
cantly longer than those in the PNSG (p  0.03).
TABLE 3. Multivariate Analysis of Prognostic Factors
Among Patients Who Underwent Adjuvant Chemotherapy
Based on the HDRA
Variables Odds Ratio 95% CI p
Adjuvant chemotherapy based on
the HDRA (PSG)
0.249 0.067–0.924 0.037
Age (65 yr) 0.466 0.160–1.358 0.161
Sex (female) 0.438 0.083–2.316 0.331
Pathological T factor (T1  T2) 0.498 0.148–1.678 0.260
Pathological N factor (negative) 0.525 0.116–2.365 0.401
Curability (complete resection) 0.524 0.089–3.091 0.475
CI, confidence interval; HDRA, Histoculture Drug Response Assay; PSG, predic-
tion-sensitive group.
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tively, with an accuracy of 83.0%) was observed. In another
study, they evaluated the chemosensitivities to gefitinib of
NSCLC using the HDRA.16 A significant relationship between
the rate of inhibition and gefitinib concentration was observed
(p  0.016). They concluded that the HDRA could evaluate
gefitinib sensitivity in NSCLC. The HDRA has also been used
to determine the influence of class III -tublin expression in
patients with completely resected NSCLC.27
We have performed the HDRA to assess 482 fresh
surgical specimens, and the assay failed in 68 cases. There-
fore, the rate at which the HDRA could be applied for
evaluation was 85.8% (414/482). This rate is considered to be
higher than that of other assays. This finding is congruent
with other studies concerning a variety of cancers, including
head and neck,28,29 gastrointestinal tract,9,10,30,31 breast,32,33
and urological cancer.34 The reason for this is that HDRA
facilitates a native-state histoculture including tissue archi-
tecture, tumor-stromal interaction and differentiated func-
tions, a long-term cell culture, and long-term exposure to
time-dependent anticancer drugs.7,35 The HDRA offers the
advantage of the very high-level preservation of the in vivo
tissue architecture observed in vitro compared with other
chemosensitivity tests. However, for effectiveness, the
HDRA requires a large amount of tissue, and so application
is limited. To obtain sufficient specimens for the HDRA,
some surgical procedures must be performed even for inop-
erable cases. In resectable cases, we can obtain a sufficient
amount of specimen on the radical resection of lung cancer
and use the results of the HDRA for adjuvant chemotherapy.
A mean of 1.4  1.2 (min–max: 0–6) HDRA-positive drugs
was obtained. Cases showing no positive drugs totaled 25.8%
(107/414), and cases showing 2 or more positive drugs
totaled 39.6% (164/414). This finding was congruent with a
previous study reporting the HDRA in NSCLC.13
If we conclude that in vitro chemosensitivity test-
guided chemotherapy improves patient survival, we should
show that chemosensitivity is not associated in any way with
the biologic behavior of cancer cells. So, we divided patients
with pathologic stages I to IV NSCLC who had undergone
the HDRA but had not received sufficient chemotherapy after
the operation into high-sensitive (82 patients who showed
two or more HDRA-positive drugs) and low-sensitive (102
patients who showed one or no HDRA-positive drugs) groups
and compared the prognoses. There were no significant dif-
ferences in sex (males/females: 61/21 and 72/30, respec-
tively, p  0.56), histology (adnocarcinoma/sqamous cell
carcinoma/others: 51/28/3 and 73/22/7, respectively, p 
0.13), pathologic stage (IA/IB/IIA/IIB/IIIA/IIIB/IV: 29/31/8/
3/7/0/4 and 42/29/6/8/8/0/9 respectively, p  0.37), patho-
logic T-factor (T1a/T1b/T2a/T2b/T3/T4: 13/17/37/8/4/3 and
17/26/37/6/15/1, respectively, p  0.16), pathologic N-factor
(N0/N1/N2: 73/4/5 and 87/6/9, respectively, p  0.74), and
survival rate between the two groups (5-year survival rate:
54.2% and 72.6%, respectively, p  0.25). This means that
sensitivity to anticancer drugs based on the HDRA itself is
not a prognostic factor, as described in a previous report on
the HDRA in patients with gastric carcinoma9 and the CD-
DST in patients with NSCLC.36
Because the number of cases in this retrospective study
was limited and the follow-up period was short (average
period: 29.2 months), a definite conclusion is difficult. How-
ever, the prognosis of the PSG was significantly better than
that of the PNSG, and so adjuvant chemotherapy based on the
HDRA is expected to improve survival. The HDRA seems to
be useful for the selection of anticancer drugs in chemother-
apy after surgery, although it is necessary to increase the
number of cases in the future and extend the period of
surveillance. This will be confirmed in a proper randomized
control study of the HDRA comparing patient survival on
receiving CDDP-containing regimens versus a PSG.
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